Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This Stock Is Down By 13% This Year: Here's Why It's a Buy

TheMotleyFool

0 0

This Stock Is Down By 13% This Year: Here's Why It's a Buy

It's been a mixed year for pharma giant Pfizer (NYSE: PFE). While the company's coronavirus-related portfolio continues to hit it out of the park, its shares have dropped by 13% since the beginning of the year. True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. The good news is that there are excellent reasons to get in on this top drugmaker at current levels. Here's why Pfizer looks like a buy right now.